Lupin launches Divalproex Sodium ER Tablets
22nd Sep 2020

Lupin has launched Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will be manufactured at Lupin’s Nagpur facility in India. Divalproex Sodium Extended-Release (ER) Tablets USP (RLD: Depakote ER) had annual sales of approximately $130 million in the U.S.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.